Breaking News Instant updates and real-time market news.

XENE

Xenon Pharmaceuticals

$16.64 /

+0.75 (+4.72%)

08:56
01/13/20
01/13
08:56
01/13/20
08:56

Xenon Pharmaceuticals announces 2020 milestone opportunities

XEN1101 is a differentiated Kv7 potassium channel modulator being developed for the treatment of epilepsy and potentially other neurological disorders. A Phase 2b double-blind, placebo-controlled, multicenter clinical trial is underway to evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive treatment in approximately 300 adult patients with focal epilepsy. The primary endpoint is the median percent change in monthly focal seizure frequency from baseline compared to treatment period of active versus placebo. Patient enrollment for this XEN1101 Phase 2b clinical trial is ongoing in the United States, Canada and Europe. Long term six-and nine-month toxicology studies have now been completed, providing support for the 12-month open label extension for patients enrolled in the Phase 2b clinical trial. Depending upon the rate of enrollment, top-line results are anticipated in the second half of 2020. Xenon continues to explore the development of XEN1101 in other neurological indications. XEN496 is a Kv7 potassium channel modulator being developed by Xenon. The U.S. Food and Drug Administration has granted orphan drug designation for XEN496 as a treatment of KCNQ2 developmental and epileptic encephalopathy. A pharmacokinetic study testing Xenon's proprietary pediatric formulation of ezogabine in healthy adult volunteers is expected to complete in the first quarter of 2020. The FDA previously indicated that it is acceptable to study XEN496 in infants and children up to four years old, and that a single, small pivotal trial may be considered adequate in order to demonstrate XEN496's efficacy in KCNQ2-DEE, provided the study shows evidence of a clinically meaningful benefit in patients with the intended indication. After completion of the XEN496 PK study and discussions with the FDA on a Phase 3 clinical trial design in the first quarter of 2020, Xenon expects to initiate a Phase 3 clinical trial in KCNQ2-DEE. XEN007 is a CNS-acting calcium channel modulator that modulates Cav2.1 and T-type calcium channels. Other reported mechanisms include dopamine, histamine and serotonin inhibition. A physician-led, Phase 2 proof-of-concept study has recently been initiated to examine the potential clinical efficacy, safety, and tolerability of XEN007 as an adjunctive treatment in pediatric patients diagnosed with treatment-resistant childhood absence epilepsy. Results from this Phase 2 investigator-led proof-of-concept study are expected in 2020. Depending on the results from the study, CAE may represent a potential orphan indication for future development of XEN007. In December 2019, Xenon entered into a license and collaboration agreement with Neurocrine Biosciences to develop first-in-class treatments for epilepsy. Neurocrine Biosciences has an exclusive license to XEN901, now known as NBI-921352, a clinical stage selective Nav1.6 sodium channel inhibitor for epilepsy. In addition, Neurocrine Biosciences gained an exclusive license to pre-clinical compounds for development, including selective Nav1.6 inhibitors and dual Nav1.2/1.6 inhibitors. The agreement also included a multi-year research collaboration to discover, identify and develop additional novel Nav1.6 and Nav1.2/1.6 inhibitors. Neurocrine Biosciences anticipates filing an IND application with the FDA in mid-2020 in order to start a Phase 2 clinical trial in SCN8A developmental and epileptic encephalopathy patients in the second half of 2020. Xenon is eligible to receive up to $25 million upon the FDA acceptance of an IND for NBI-921352, with 55% of the amount in the form of an equity investment in Xenon at a 15% premium to Xenon's 30-day trailing volume weighted average price at that time. In September 2019, Xenon entered into an agreement with Flexion Therapeutics that provides Flexion with the global rights to develop and commercialize XEN402, a Nav1.7 inhibitor. Flexion's pre-clinical program, known as FX301, consists of XEN402 formulated for extended release from a thermosensitive hydrogel. The initial development of FX301 is intended to support administration as a peripheral nerve block for control of post-operative pain. Flexion has indicated that it anticipates initiating FX301 clinical trials in 2021. Effective immediately, Dr. Clarissa Desjardins has been appointed to Xenon's Board of Directors and will also serve on the Compensation Committee. An award-winning entrepreneur with over 25 years of biotechnology experience, Dr. Desjardins has a doctorate in neurology and neurosurgery from McGill University's Faculty of Medicine. In 2011, Dr. Desjardins founded Clementia Pharmaceuticals, a publicly traded biotechnology company focused on rare bone disorders that was acquired by Ipsen S.A. in 2019 for up to $1.3 billion. Dr. Richard Scheller will resign from Xenon's Board effective January 14, 2020 after serving as an independent director since 2015.

XENE Xenon Pharmaceuticals
$16.64 /

+0.75 (+4.72%)

03/29/19 STFL
Xenon Pharmaceuticals price target raised, coverage transferred at Stifel
09/20/19 GUGG
Xenon Pharmaceuticals initiated with a Buy at Guggenheim
09/20/19 GUGG
Guggenheim starts Xenon Pharmaceuticals at Buy, sees good odds for lead asset
01/08/20 WBLR
Xenon Pharmaceuticals initiated with an Outperform at William Blair

TODAY'S FREE FLY STORIES

Conference/Events
Naitonal Marine Manufacturers Association to hold ashow » 04:55
01/26/20
01/26
04:55
01/26/20
04:55

New York Boat Show will…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Periodicals
HP stock 'a good bet,' Barron's says » 14:56
01/25/20
01/25
14:56
01/25/20
14:56
XRX

Xerox

$35.52 /

-0.71 (-1.96%)

, HPQ

HP Inc.

$21.99 /

-0.115 (-0.52%)

For more than two months…

For more than two months now, Xerox (XRX) has been pushing HP Inc. (HPQ) to accept its $32B, $22 a share takeover bid and now it is done asking, with Xerox launching a proxy fight for control of HP and nominating 11 directors to replace the latter's entire board, Eric Savitz writes in this week's edition of Barron's. HP has made it clear that it would prefer to lever up and buy back huge amounts of stock, rather than submit to a Xerox offer that it considers inadequate, but a higher bid could soften HP's position, the author notes. In either scenario, HP investors are likely to benefit, the report adds. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Investors should run away from ad agencies despite Super Bowl, Barron's says » 14:43
01/25/20
01/25
14:43
01/25/20
14:43
BUD

AB InBev

$77.74 /

-0.47 (-0.60%)

, FB

Facebook

$217.89 /

-1.76 (-0.80%)

, OMC

Omnicom

$77.71 /

-1.05 (-1.33%)

, IPG

Interpublic Group

$23.41 /

-0.13 (-0.55%)

, PUBGY

Publicis

$0.00 /

+ (+0.00%)

, WPP

WPP

$65.07 /

-0.81 (-1.23%)

, GOOG

Alphabet

$1,466.47 /

-19.67 (-1.32%)

, GOOGL

Alphabet Class A

$1,465.80 /

-19.06 (-1.28%)

, ACN

Accenture

$208.56 /

-2.16 (-1.03%)

, IBM

IBM

$140.54 /

-2.36 (-1.65%)

, CRM

Salesforce

$182.11 /

-1.89 (-1.03%)

, ORCL

Oracle

$54.07 /

-0.91 (-1.66%)

Super Bowl commercials…

Super Bowl commercials this year will feature a healthy mix of regulars like Bud Light (BUD), brands returning from long breaks and first timers like Facebook (FB) Jack Hough writes in this week's edition of Barron's. Bu shares of big, pure-play advertising agencies - like Omnicom Group (OMC) and Interpublic Group (IPG) in the U.S., Publicis Groupe (PUBGY) in Paris, and WPP (WPP) in London - may hold less appeal than modest valuations advertise, he contends. The long shift of advertising dollars from traditional venues to platforms such as Facebook and Google (GOOG) has prompted technology companies to get in on the marketing game, and agencies competing with one another for new accounts might also find themselves defending against Accenture (ACN), IBM (IBM), Salesforce.com (CRM), and Oracle (ORCL). Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Big techs competing for bigger slice of esports business, Barron's says » 14:35
01/25/20
01/25
14:35
01/25/20
14:35
ATVI

Activision Blizzard

$59.36 /

-0.77 (-1.28%)

, GOOGL

Alphabet Class A

$1,465.80 /

-19.06 (-1.28%)

, GOOG

Alphabet

$1,466.47 /

-19.67 (-1.32%)

, MSFT

Microsoft

$165.03 /

-1.69 (-1.01%)

, AMZN

Amazon.com

$1,862.09 /

-22.76 (-1.21%)

Big tech companies,…

Big tech companies, including Amazon (AMZN), Microsoft (MSFT), and Alphabet (GOOGL), are competing for a bigger slice of the esports live-streaming business, which could present an opportunity for investors, Connor Smith writes in this week's edition of Barron's. Esports events - where the best players compete in games like League of Legends, Activision Blizzard's (ATVI) Overwatch, and Valve's Dota 2 and Counter-Strike: Global Offensive - are attracting young people, much the way traditional sports had for generations, the author notes. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Investors can buy into sports teams, valuation lofty, Barron's says » 14:28
01/25/20
01/25
14:28
01/25/20
14:28
MSG

Madison Square Garden

$296.18 /

-0.47 (-0.16%)

, MANU

Manchester United

$18.97 /

-0.04 (-0.21%)

, BATRK

Liberty Braves

$29.15 /

-0.13 (-0.44%)

Investors can buy shares…

Investors can buy shares in the Atlanta Braves (BATRK) or Manchester United (MANU) and soon they will be able to do the same with the New York Knicks and New York Rangers after Madison Square Garden (MSG) splits off its entertainment businesses from its sports operations, which it may do sometime this year, Nicholas Jasinski writes in this week's edition of Barron's. While each is a real business, with revenues and profits, their stocks are driven more by private transaction valuations than they are by fundamentals, the author contended, adding that while the teams are unusual investments, at least they are investments. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Sports gambling will be 'huge opportunity,' Barron's says » 08:37
01/25/20
01/25
08:37
01/25/20
08:37
DEAC

Diamond Eagle Acquisition

$14.39 /

-0.03 (-0.21%)

, PDYPY

Flutter Entertainment

$0.00 /

+ (+0.00%)

Super Bowl is the biggest…

Super Bowl is the biggest day of the year for sports gambling and this year an increasing share of the wagering on the February 2 game between the San Francisco 49ers and the Kansas City Chiefs will be done legally, Andrew Bary writes in this week's edition of Barron's. Sports betting has quickly become the hottest trend in the U.S. gambling industry, with the latter focusing its expansion on mobile sports gambling, rather than the sports books patterned on those at Las Vegas casinos, the author notes. The Street's enthusiasm is most evident in the surging stock price of Diamond Eagle Acquisition (DEAC), a special purpose acquisition company, or SPAC, that reached a deal in late December to buy DraftKings, the report adds. The other chief play on U.S. sports gambling is Flutter Entertainment (PDYPY), the top U.K. betting company that controls FanDuel, the main online U.S. sports wagering rival for DraftKings. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

On The Fly
Week in Review: How Trump's policies moved stocks » 08:12
01/25/20
01/25
08:12
01/25/20
08:12
GOOG

Alphabet

$1,466.47 /

-19.67 (-1.32%)

, GOOGL

Alphabet Class A

$1,465.80 /

-19.06 (-1.28%)

, AAPL

Apple

$318.25 /

-1.02 (-0.32%)

, FB

Facebook

$217.89 /

-1.76 (-0.80%)

, AMZN

Amazon.com

$1,862.09 /

-22.76 (-1.21%)

, MSFT

Microsoft

$165.03 /

-1.69 (-1.01%)

, CNC

Centene

$66.58 /

-1.5 (-2.20%)

, UNH

UnitedHealth

$292.89 /

-6.51 (-2.17%)

, CVS

CVS Health

$71.44 /

-2.08 (-2.83%)

, CI

Cigna

$206.12 /

-6.59 (-3.10%)

, SIEGY

Siemens

$0.00 /

+ (+0.00%)

Catch up on the top…

Open Full Text

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
American Society of Clinical Oncology to hold a symposium » 04:55
01/25/20
01/25
04:55
01/25/20
04:55
AMZN

Amazon.com

$1,862.09 /

-22.76 (-1.21%)

, AGIO

Agios Pharmaceuticals

$53.04 /

-0.22 (-0.41%)

, AZN

AstraZeneca

$49.28 /

-0.93 (-1.85%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$64.18 /

-2.715 (-4.06%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, DSNKY

Daiichi Sankyo

$0.00 /

+ (+0.00%)

, ERYP

Erytech Pharma

$7.10 /

+ (+0.00%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, EXEL

Exelixis

$18.01 /

-1.57 (-8.02%)

, FGEN

FibroGen

$41.80 /

-2.35 (-5.32%)

, HSDEF

Harborside

$0.00 /

+ (+0.00%)

, INCY

Incyte

$76.66 /

-1.56 (-1.99%)

, LXRX

Lexicon

$3.37 /

-0.07 (-2.03%)

, MRK

Merck

$85.96 /

-2.56 (-2.89%)

, NTRA

Natera

$35.71 /

-1.08 (-2.94%)

, NVTA

Invitae

$18.35 /

-0.15 (-0.81%)

, PFE

Pfizer

$39.82 /

-0.89 (-2.19%)

, PGNX

Progenics

$4.65 /

-0.045 (-0.96%)

, SGEN

Seattle Genetics

$113.63 /

-1.69 (-1.47%)

, TROV

Trovagene

$1.69 /

-0.075 (-4.25%)

2020 Gastrointestinal…

2020 Gastrointestinal Cancers Symposium will be held in San Francisco on January 23-25.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Naitonal Marine Manufacturers Association to hold ashow » 04:55
01/25/20
01/25
04:55
01/25/20
04:55

New York Boat Show will…

New York Boat Show will be held in New York on January 22-26.

Conference/Events
Crohn's & Colitis Foundation to hold a conference » 04:55
01/25/20
01/25
04:55
01/25/20
04:55
ABBV

AbbVie

$83.53 /

-1.73 (-2.03%)

, ARNA

Arena Pharmaceuticals

$44.54 /

-1.27 (-2.77%)

, BMY

Bristol-Myers

$64.18 /

-2.715 (-4.06%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, GILD

Gilead

$63.12 /

-0.84 (-1.31%)

, LLY

Eli Lilly

$139.09 /

-2.14 (-1.52%)

, PFE

Pfizer

$39.82 /

-0.89 (-2.19%)

, TAK

Takeda Pharmaceutical

$19.84 /

-0.185 (-0.92%)

, UCBJF

UCB

$0.00 /

+ (+0.00%)

, UCBJY

UCB

$0.00 /

+ (+0.00%)

2020 Crohn's &…

2020 Crohn's & Colitis Congress will be held in Austin, Texas on January 23-25.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Babcock & Wilcox says continues to work toward refinancing debt » 18:33
01/24/20
01/24
18:33
01/24/20
18:33
BW

Babcock & Wilcox

$4.55 /

+ (+0.00%)

Babcock & Wilcox…

Babcock & Wilcox announced that the company continues to work toward refinancing its current senior debt and extending its maturity and, as a result, has entered into an Amendment to further extend the deadline for completing certain required corporate actions in connection with the refinancing of its existing Credit Agreement. The deadline to complete these actions has been extended from January 20 to January 31. As previously disclosed, the company is required to refinance by March 15. "We are continuing to work closely with our existing lenders to reach an agreement that will provide long-term restructuring of our debt," said Kenneth Young, B&W CEO. "We expect to make a further announcement regarding the agreement on or before January 31, 2020."

General news
Weekly CFTC Commitment of Traders highlights » 17:56
01/24/20
01/24
17:56
01/24/20
17:56
IEF

iShares 7-10 Year Treasury Bond ETF

$112.45 /

+0.395 (+0.35%)

, SHY

iShares 1-3 Year Treasury Bond

$84.88 /

+0.035 (+0.04%)

, SPY

SPDR S&P 500 ETF Trust

$328.73 /

-2.99 (-0.90%)

, SLV

iShares Silver Trust

$16.91 /

+0.29 (+1.74%)

, GLD

SPDR Gold Shares

$147.96 /

+0.85 (+0.58%)

, FXE

Euro Currency Trust

$104.46 /

-0.28 (-0.27%)

2-YEAR U.S. TREASURY net…

2-YEAR U.S. TREASURY net short 321.4K contracts, up 39.7K from prior week... 10-YEAR U.S. TREASURY net short 302.5K contracts, up 79.0K from prior week and a 4-month high in net shorts... 30-DAY FED FUNDS FUTURES net long 355.9K contracts, down 41.1K from prior week and a 3-week low in net longs... CONSOLIDATED S&P 500 FUTURES net long 4.6K contracts, down 3.9K from prior week and a 5-week low in net longs... E-MINI RUSSELL FUTURES net long 54.3K contracts, up 5.6K from prior week and an 18-month high in net longs... U.S. DOLLAR INDEX net long 12.9K contracts, down 0.3K from prior week... EURO net short 47.0K contracts, down 1.2K from prior week and a 5-month low in net shorts... BRITISH POUND net long 24.9K contracts, down 6.6K from prior week... JAPANESE YEN net short 44.7K contracts, up 13.3K from prior week and a 7-week high in net shorts... SWISS FRANC net long 1.5K contracts, first net long position since December 2016... AUSTRALIAN DOLLAR net short 19.3K contracts, down 1.2K from prior week and a 19-month low in net shorts... NEW ZEALAND DOLLAR net long 1.8K contracts, first net long position since March 2019... CANADIAN DOLLAR net long 38.3K contracts, up 5.4K from prior week and a 2-month high in net longs... MEXICAN PESO net long 167.0K contracts, up 4.3K from prior week and a multi-year high in net longs... CRUDE OIL net long 520.6K contracts, down 9.7K from prior week and a 6-week low in net longs... GOLD net long 317.7K contracts, down 1.5K from prior week and a 4-week low in net longs... SILVER net long 68.9K contracts, up 1.5K from prior week and a 3-week high in net longs... COPPER net long 5.8K contracts, up 2.3K from prior week and a 19-month high in net longs.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Consolidated-Tomoka acquires retail center in AZ for $61.8M » 17:54
01/24/20
01/24
17:54
01/24/20
17:54
CTO

Consolidated-Tomoka

$64.50 /

+0.05 (+0.08%)

Consolidated-Tomoka…

Consolidated-Tomoka announced the purchase of Crossroads Towne Center, an approximately 25K square foot retail center in Chandler, Arizona, for $61.8M, representing a going-in cap rate of approximately 7.85%. The weighted average lease term for the leases of all 32 tenants at Crossroads is approximately 5 years.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
9 state AGs urge judge to dismiss Google's 'Wi-Spy' settlement, Bloomberg says » 17:44
01/24/20
01/24
17:44
01/24/20
17:44
GOOG

Alphabet

$1,466.47 /

-19.67 (-1.32%)

, GOOGL

Alphabet Class A

$1,465.80 /

-19.06 (-1.28%)

Attorneys general from…

Attorneys general from nine U.S. states are urging a federal judge to dismiss Google's $13M settlement of a class-action lawsuit claiming that its Street View mapping technology violated consumer privacy, Bloomberg's Malathi Nayak reports. The proposed settlement in a matter that became known as "Wi-Spy" does not offer compensation for millions of people whose confidential information was captured off their Wi-FI networks by Street View vehicles, and instead the accord divvies up funds among a handful of privacy rights organizations, a small number of individual consumers who led the case, and their attorneys, Nayak says, citing the state officials in a court filing. "Without receiving any of the $13 million cash fund or any meaningful injunctive relief, class members receive no direct benefit from the settlement," the attorneys general said. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
PG&E probation judge threatens to restrict pay bonuses, Bloomberg says » 17:40
01/24/20
01/24
17:40
01/24/20
17:40
PCG

PG&E

$14.27 /

+0.51 (+3.71%)

PG&E Corp. (PCG)…

PG&E Corp. (PCG) could be ordered by probation judge William Alsup to "restrict bonuses and incentives for supervisors and other high-ranking employees until the company meets its obligations under its wildfire-prevention plan," according to Bloomberg's Peter Blumberg and Mark Chediak. The judge additionally threatened to tie incentive pay to the company meeting its fire mitigation and safety goals. The judge has asked PG&E to explain why he shouldn't issue such an order, the report added. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Four Corners Property Trust acquires recreational equipment property for $5.2M » 17:40
01/24/20
01/24
17:40
01/24/20
17:40
FCPT

Four Corners Property Trust

$29.72 /

+0.275 (+0.93%)

, PEI

Pennsylvania REIT

$4.50 /

-0.37 (-7.60%)

Four Corners Property…

Four Corners Property Trust (FCPT) announced the acquisition of a recreational equipment property for $5.2M as part of a previously announced outparcel transaction with Pennsylvania REIT (PEI). The property is located in Michigan and is occupied under a net lease with nine years of term remaining. The property is newly constructed and is leased to the corporate operator. This transaction is the second closing of the previously announced PREIT portfolio transaction in November, priced at a 6.5% going-in cash cap rate, on a portfolio basis, exclusive of transaction costs.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Syndicate
H.B. Fuller files automatic mixed securities shelf  17:33
01/24/20
01/24
17:33
01/24/20
17:33
FUL

H.B. Fuller

$48.35 /

-0.69 (-1.41%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Syndicate
Suzano files automatic mixed securities shelf  17:26
01/24/20
01/24
17:26
01/24/20
17:26
SUZ

Suzano

$10.38 /

-0.28 (-2.63%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Syndicate
Document Security files to sell $6M in common stock » 17:22
01/24/20
01/24
17:22
01/24/20
17:22
DSS

Document Security

$0.30 /

-0.0225 (-6.98%)

Aegis Capital acted as…

Aegis Capital acted as sole book running manager for the offering.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Syndicate
New Frontier Health files to sell 127.34M ordinary shares for holders » 17:10
01/24/20
01/24
17:10
01/24/20
17:10
NFH

New Frontier Health

$9.45 /

+0.105 (+1.12%)

Also files to sell 12.5M…

Also files to sell 12.5M warrants for holders.

Syndicate
New Frontier Health files to sell 26.875M ordinary shares  17:09
01/24/20
01/24
17:09
01/24/20
17:09
NFH

New Frontier Health

$9.45 /

+0.105 (+1.12%)

 
Syndicate
Willamette Valley Vineyards files $20M mixed securities shelf  17:08
01/24/20
01/24
17:08
01/24/20
17:08
WVVI

Willamette Valley Vineyards

$6.75 /

-0.14 (-2.03%)

 
Hot Stocks
Ashland appoints Dr. Xiaolan Wang to lead Personal Care business unit » 17:04
01/24/20
01/24
17:04
01/24/20
17:04
ASH

Ashland

$75.33 /

-0.66 (-0.87%)

Ashland announced Dr.…

Ashland announced Dr. Xiaolan Wang will be joining the company to lead the Personal Care business unit, effective February 1. Wang will report directly to CEO Guillermo Novo. Most recently Wang had global P&L responsibility for a diverse specialty additive business at Evonik. Previously, she held leadership roles at Dow, Rohm & Haas, and ICI.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
eHealth CEO sells 121K shares of common stock » 16:59
01/24/20
01/24
16:59
01/24/20
16:59
EHTH

eHealth

$123.20 /

+26.11 (+26.89%)

In a regulatory filing,…

In a regulatory filing, eHealth disclosed that its CEO Scott Flanders sold 121K shares of common stock on January 22nd-24th. The total transaction size was about $13.3M.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Syndicate
Can-Fite BioPharma files to sell $5M of units  16:43
01/24/20
01/24
16:43
01/24/20
16:43
CANF

Can-Fite BioPharma

$2.71 /

+0.02 (+0.74%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.